AstraZeneca Announces Plans for New Strategic R&D Center

AstraZeneca announced on April 29, 2022 its plans to open a new strategic R&D center in Kendall Square, Cambridge, Mass. The new site will also serve as Alexion’s new corporate headquarters, a company which AstraZeneca owns.

The site will bring together approximately 1500 R&D, commercial, and corporate colleagues into a single purpose-built space. It is scheduled to be completed in 2026 and is strategically located to be near several major academic, pharma, and biotech institutions, which can be helpful for collaborations and access to future talent. The new site reinforces AstraZeneca’s Boston expansion with more than 570,000 square feet of R&D and commercial space as well as expansion for the future.

“Today’s announcement is a milestone moment following the acquisition of Alexion in July 2021,” said Pascal Soriot, CEO of AstraZeneca, in a press release. “Our combined company has already successfully leveraged internal scientific synergies, and this move will act as a catalyst for even more external collaboration and innovation. Kendall Square, Cambridge, is at the heart of the life sciences and innovation hub of the greater Boston area, and our new site will put us right at the center of this space. The move will provide access to some of the most innovative partners in academia and biotech, offering opportunities to accelerate our growth and collaborate with like-minded organizations as we continue to push the boundaries of science to deliver advances for patients.”